Amylyx Pharmaceuticals Cash Flow Statement
NASDAQ: AMLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
28.14+0.94 (+3.46%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amylyx Pharmaceuticals free cash flow
In fiscal 2025, Amylyx Pharmaceuticals generated -$123.3 million of operating cash flow and spent $138,000 on capital expenditures. That left free cash flow of -$123.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
Amylyx Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 |
|---|---|---|---|---|---|
| Net Income | -144.74M | -301.74M | 49.27M | -198.38M | -87.93M |
| Net Income growth (YoY) | — | -712.42% | — | — | — |
| Depreciation & Amortization | 525.00K | 904.00K | 1.09M | 487.00K | 52.00K |
| Stock-Based Compensation | 27.64M | 33.04M | 37.16M | 21.71M | 3.14M |
| Change in Working Capital | 301.00K | -46.56M | -60.63M | -23.68M | 795.00K |
| Operating Cash Flow | -123.34M | -167.65M | 11.92M | -179.87M | -74.80M |
| Capital Expenditures | -138.00K | -157.00K | -1.24M | -2.53M | -353.00K |
| Investing Cash Flow | 14.04M | 75.65M | 92.05M | -238.99M | -46.41M |
| Debt Issued | 256.31M | — | — | — | 11.89M |
| Financing Cash Flow | 257.03M | 348.00K | 3.54M | 431.79M | 158.51M |
| Net Change in Cash | 148.80M | -92.08M | 107.67M | 12.87M | 37.31M |
| Free Cash Flow | -123.48M | -167.80M | 10.68M | -182.40M | -75.15M |
This table shows 5 annual periods of Amylyx Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2021, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AMLX's reporting calendar. What is a cash flow statement?